Question:
You are tasked with answering the user's question using the provided context, which includes financial statements (Income Statements, Balance Sheets, and Cash Flow Statements) and financial news articles in multiple languages (English, Chinese, Japanese, Spanish, and Greek). Please provide a detailed and well-supported answer based on the information available. Limit your response to 100 words or fewer. If you cannot answer the question or if no relevant evidence is found, write “None”.

Answer Format:
Answer: {Answer by summarizing the financial news.}
Financial Statements Evidence: {Verify your answer using quote(s) from the financial statements (include original amounts if relevant). Write “None” if no statement evidence is available.}
Context:
Financial Statements:
| Column 1                                                                                | Column 2   | Column 3       | Column 4   | Column 5          | Column 6   | Column 7   | Column 8   | Column 9   | Column 10   | Column 11   | Column 12   | Column 13   | Column 14   | Column 15   |
|:---------------------------------------------------------------------------------------------------|:-----------|:---------------|:-----------|:------------------|:-----------|:-----------|:-----------|:-----------|:------------|:------------|:------------|:------------|:------------|:------------|
|                                                                                |            |                |            |                   |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            | March 30, 2025 |            | December 29, 2024 |            |            |            |            |             |             |             |             |             |             |
| Assets                                                                                |            |                |            |                   |            |            |            |            |             |             |             |             |             |             |
| Current assets:                                                                                |            |                |            |                   |            |            |            |            |             |             |             |             |             |             |
| Cash and cash equivalents (Note 4)                                                                 |            | $38,474        |            | 24,105            |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |                |            |                   |            |            |            |            |             |             |             |             |             |             |
| Marketable securities                                                                              |            | 307            |            | 417               |            |            |            |            |             |             |             |             |             |             |
| Accounts receivable, trade, less allowances $170(2024, $167)                                       |            | 16,020         |            | 14,842            |            |            |            |            |             |             |             |             |             |             |
| Inventories (Note 2)                                                                               |            | 12,659         |            | 12,444            |            |            |            |            |             |             |             |             |             |             |
| Prepaid expenses and other                                                                         |            | 4,091          |            | 4,085             |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |                |            |                   |            |            |            |            |             |             |             |             |             |             |
| Total current assets                                                                               |            | 71,551         |            | 55,893            |            |            |            |            |             |             |             |             |             |             |
| Property, plant and equipment at cost                                                              |            | 49,884         |            | 48,768            |            |            |            |            |             |             |             |             |             |             |
| Less: accumulated depreciation                                                                     |            | (29,013)       |            | (28,250)          |            |            |            |            |             |             |             |             |             |             |
| Property, plant and equipment, net                                                                 |            | 20,871         |            | 20,518            |            |            |            |            |             |             |             |             |             |             |
| Intangible assets, net (Note 3)                                                                    |            | 36,755         |            | 37,618            |            |            |            |            |             |             |             |             |             |             |
| Goodwill (Note 3)                                                                                |            | 44,468         |            | 44,200            |            |            |            |            |             |             |             |             |             |             |
| Deferred taxes on income (Note 5)                                                                  |            | 8,492          |            | 10,461            |            |            |            |            |             |             |             |             |             |             |
| Other assets                                                                                |            | 11,534         |            | 11,414            |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |                |            |                   |            |            |            |            |             |             |             |             |             |             |
| Total assets                                                                                |            | $193,671       |            | 180,104           |            |            |            |            |             |             |             |             |             |             |
| Liabilities and shareholders’ equity                                                               |            |                |            |                   |            |            |            |            |             |             |             |             |             |             |
| Current liabilities:                                                                               |            |                |            |                   |            |            |            |            |             |             |             |             |             |             |
| Loans and notes payable                                                                            |            | $13,897        |            | 5,983             |            |            |            |            |             |             |             |             |             |             |
| Accounts payable                                                                                |            | 9,545          |            | 10,311            |            |            |            |            |             |             |             |             |             |             |
| Accrued liabilities                                                                                |            | 7,913          |            | 8,549             |            |            |            |            |             |             |             |             |             |             |
| Accrued rebates, returns and promotions                                                            |            | 18,780         |            | 17,580            |            |            |            |            |             |             |             |             |             |             |
| Accrued compensation and employee related obligations                                              |            | 2,551          |            | 4,126             |            |            |            |            |             |             |             |             |             |             |
| Accrued taxes on income (Note 5)                                                                   |            | 4,217          |            | 3,772             |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |                |            |                   |            |            |            |            |             |             |             |             |             |             |
| Total current liabilities                                                                          |            | 56,903         |            | 50,321            |            |            |            |            |             |             |             |             |             |             |
| Long-term debt (Note 4)                                                                            |            | 38,355         |            | 30,651            |            |            |            |            |             |             |             |             |             |             |
| Deferred taxes on income (Note 5)                                                                  |            | 2,428          |            | 2,448             |            |            |            |            |             |             |             |             |             |             |
| Employee related obligations (Note 6)                                                              |            | 7,046          |            | 7,255             |            |            |            |            |             |             |             |             |             |             |
| Long-term taxes payable (Note 5)                                                                   |            | 395            |            | 390               |            |            |            |            |             |             |             |             |             |             |
| Other liabilities                                                                                |            | 10,435         |            | 17,549            |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |                |            |                   |            |            |            |            |             |             |             |             |             |             |
| Total liabilities                                                                                |            | $115,562       |            | 108,614           |            |            |            |            |             |             |             |             |             |             |
| Commitments and Contingencies (Note 11)                                                            |            |                |            |                   |            |            |            |            |             |             |             |             |             |             |
| Shareholders’ equity:                                                                              |            |                |            |                   |            |            |            |            |             |             |             |             |             |             |
| Common stock — par value $1.00per share (authorized4,320,000,000shares; issued3,119,843,000shares) |            | $3,120         |            | 3,120             |            |            |            |            |             |             |             |             |             |             |
| Accumulated other comprehensive income (loss) (Note 7)                                             |            | (11,740)       |            | (11,741)          |            |            |            |            |             |             |             |             |             |             |
| Retained earnings and Additional paid-in capital                                                   |            | 162,635        |            | 155,791           |            |            |            |            |             |             |             |             |             |             |
| Less: common stock held in treasury, at cost (714,218,000and712,921,000shares)                     |            | 75,906         |            | 75,680            |            |            |            |            |             |             |             |             |             |             |
| Total shareholders’ equity                                                                         |            | $78,109        |            | 71,490            |            |            |            |            |             |             |             |             |             |             |
| Total liabilities and shareholders’ equity                                                         |            | $193,671       |            | 180,104           |            |            |            |            |             |             |             |             |             |             |

---

| Column 1                                                                                | Column 2   | Column 3                  | Column 4   | Column 5      | Column 6   | Column 7   | Column 8   | Column 9   | Column 10   | Column 11   | Column 12   | Column 13   | Column 14   | Column 15   |
|:------------------------------------------------------------------------------------------|:-----------|:--------------------------|:-----------|:--------------|:-----------|:-----------|:-----------|:-----------|:------------|:------------|:------------|:------------|:------------|:------------|
|                                                                                |            |                           |            |               |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            | Fiscal Three Months Ended |            |               |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            | March 30,2025             |            | March 31,2024 |            |            |            |            |             |             |             |             |             |             |
| Cash flows from operating activities                                                      |            |                           |            |               |            |            |            |            |             |             |             |             |             |             |
| Net earnings                                                                              |            | $10,999                   |            | 3,255         |            |            |            |            |             |             |             |             |             |             |
| Adjustments to reconcile net earnings to cash flows from operating activities:            |            |                           |            |               |            |            |            |            |             |             |             |             |             |             |
| Depreciation and amortization of property and intangibles                                 |            | 1,772                     |            | 1,815         |            |            |            |            |             |             |             |             |             |             |
| Stock based compensation                                                                  |            | 288                       |            | 302           |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |                           |            |               |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |                           |            |               |            |            |            |            |             |             |             |             |             |             |
| Asset write-downs                                                                         |            | 30                        |            | 185           |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |                           |            |               |            |            |            |            |             |             |             |             |             |             |
| Charges for purchase of in-process research and development assets                        |            | 16                        |            | —             |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |                           |            |               |            |            |            |            |             |             |             |             |             |             |
| Net gain on sale of assets/businesses                                                     |            | (75)                      |            | —             |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |                           |            |               |            |            |            |            |             |             |             |             |             |             |
| Deferred tax provision                                                                    |            | 2,172                     |            | (1,562)       |            |            |            |            |             |             |             |             |             |             |
| Credit losses and accounts receivable allowances                                          |            | (4)                       |            | —             |            |            |            |            |             |             |             |             |             |             |
| Changes in assets and liabilities, net of effects from acquisitions and divestitures:     |            |                           |            |               |            |            |            |            |             |             |             |             |             |             |
| Increase in accounts receivable                                                           |            | (926)                     |            | (279)         |            |            |            |            |             |             |             |             |             |             |
| Increase in inventories                                                                   |            | (146)                     |            | (348)         |            |            |            |            |             |             |             |             |             |             |
| Decrease in accounts payable and accrued liabilities                                      |            | (2,126)                   |            | (2,483)       |            |            |            |            |             |             |             |             |             |             |
| (Increase)/Decrease in other current and non-current assets                               |            | (1,317)                   |            | 3,199         |            |            |            |            |             |             |             |             |             |             |
| Decrease in other current and non-current liabilities                                     |            | (6,509)                   |            | (427)         |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |                           |            |               |            |            |            |            |             |             |             |             |             |             |
| Net cash flows from operating activities                                                  |            | 4,174                     |            | 3,657         |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |                           |            |               |            |            |            |            |             |             |             |             |             |             |
| Cash flows from investing activities                                                      |            |                           |            |               |            |            |            |            |             |             |             |             |             |             |
| Additions to property, plant and equipment                                                |            | (795)                     |            | (807)         |            |            |            |            |             |             |             |             |             |             |
| Proceeds from the disposal of assets/businesses, net (Note 10)                            |            | 279                       |            | 210           |            |            |            |            |             |             |             |             |             |             |
| Acquisitions, net of cash acquired (Note 10)                                              |            | —                         |            | (1,811)       |            |            |            |            |             |             |             |             |             |             |
| Acquired in-process research and development assets (Note 10)                             |            | (14)                      |            | —             |            |            |            |            |             |             |             |             |             |             |
| Purchases of investments                                                                  |            | (251)                     |            | (630)         |            |            |            |            |             |             |             |             |             |             |
| Sales of investments                                                                      |            | 218                       |            | 979           |            |            |            |            |             |             |             |             |             |             |
| Credit support agreements activity, net                                                   |            | 296                       |            | 1,600         |            |            |            |            |             |             |             |             |             |             |
| Other (including capitalized licenses and milestones)                                     |            | (30)                      |            | (5)           |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |                           |            |               |            |            |            |            |             |             |             |             |             |             |
| Net cash used by investing activities                                                     |            | (297)                     |            | (464)         |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |                           |            |               |            |            |            |            |             |             |             |             |             |             |
| Cash flows from financing activities                                                      |            |                           |            |               |            |            |            |            |             |             |             |             |             |             |
| Dividends to shareholders                                                                 |            | (2,989)                   |            | (2,869)       |            |            |            |            |             |             |             |             |             |             |
| Repurchase of common stock                                                                |            | (2,127)                   |            | (1,475)       |            |            |            |            |             |             |             |             |             |             |
| Proceeds from short-term debt, net                                                        |            | 8,784                     |            | 5,263         |            |            |            |            |             |             |             |             |             |             |
| Repayment of short-term debt, net                                                         |            | (2,120)                   |            | (890)         |            |            |            |            |             |             |             |             |             |             |
| Proceeds from long-term debt, net of issuance costs                                       |            | 9,138                     |            | 2             |            |            |            |            |             |             |             |             |             |             |
| Repayment of long-term debt                                                               |            | (751)                     |            | (1)           |            |            |            |            |             |             |             |             |             |             |
| Proceeds from the exercise of stock options/employee withholding tax on stock awards, net |            | 450                       |            | 195           |            |            |            |            |             |             |             |             |             |             |
| Credit support agreements activity, net                                                   |            | (3)                       |            | 228           |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |                           |            |               |            |            |            |            |             |             |             |             |             |             |
| Other                                                                                |            | 40                        |            | 93            |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |                           |            |               |            |            |            |            |             |             |             |             |             |             |
| Net cash from financing activities                                                        |            | 10,422                    |            | 546           |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |                           |            |               |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |                           |            |               |            |            |            |            |             |             |             |             |             |             |

---

| Column 1                                       | Column 2   | Column 3                   | Column 4   | Column 5        | Column 6   | Column 7      | Column 8   | Column 9        | Column 10   | Column 11   | Column 12   | Column 13   | Column 14   | Column 15   | Column 16   | Column 17   | Column 18   | Column 19   | Column 20   | Column 21   | Column 22   | Column 23   | Column 24   | Column 25   | Column 26   | Column 27   |
|:-----------------------------------------------|:-----------|:---------------------------|:-----------|:----------------|:-----------|:--------------|:-----------|:----------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|
|                                                |            |                            |            |                 |            |               |            |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
|                                                |            | Fiscal First Quarter Ended |            |                 |            |               |            |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
|                                                |            | March 30,2025              |            | Percentto Sales |            | March 31,2024 |            | Percentto Sales |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Sales to customers (Note 9)                    |            | $21,893                    |            | 100.0           | %          |               | $21,383    |                 | 100.0       | %           |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Cost of products sold                          |            | 7,357                      |            |                 | 33.6       |               |            | 6,511           |             | 30.4        |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Gross profit                                   |            | 14,536                     |            |                 | 66.4       |               |            | 14,872          |             | 69.6        |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Selling, marketing and administrative expenses |            | 5,112                      |            |                 | 23.3       |               |            | 5,257           |             | 24.6        |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Research and development expense               |            | 3,225                      |            |                 | 14.7       |               |            | 3,542           |             | 16.6        |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
|                                                |            |                            |            |                 |            |               |            |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Interest income                                |            | (332)                      |            |                 | (1.5)      |               |            | (364)           |             | (1.7)       |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Interest expense, net of portion capitalized   |            | 204                        |            |                 | 0.9        |               |            | 155             |             | 0.7         |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Other (income) expense, net                    |            | (7,321)                    |            |                 | (33.4)     |               |            | 2,404           |             | 11.2        |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Restructuring (Note 12)                        |            | 17                         |            |                 | 0.1        |               |            | 164             |             | 0.8         |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Earnings before provision for taxes on income  |            | 13,631                     |            |                 | 62.3       |               |            | 3,714           |             | 17.4        |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Provision for taxes on income (Note 5)         |            | 2,632                      |            |                 | 12.1       |               |            | 459             |             | 2.2         |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
|                                                |            |                            |            |                 |            |               |            |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
|                                                |            |                            |            |                 |            |               |            |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Net earnings                                   |            | $10,999                    |            |                 | 50.2       | %             |            | $3,255          |             | 15.2        | %           |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Net earnings per share (Note 8)                |            |                            |            |                 |            |               |            |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Basic                                          |            | $4.57                      |            |                 |            |               | $1.35      |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
|                                                |            |                            |            |                 |            |               |            |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
|                                                |            |                            |            |                 |            |               |            |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Diluted                                        |            | $4.54                      |            |                 |            |               | $1.34      |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
|                                                |            |                            |            |                 |            |               |            |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
|                                                |            |                            |            |                 |            |               |            |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Avg. shares outstanding                        |            |                            |            |                 |            |               |            |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Basic                                          |            | 2,407.2                    |            |                 |            |               | 2,408.2    |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Diluted                                        |            | 2,423.8                    |            |                 |            |               | 2,430.1    |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |

---

English News:
**Johnson & Johnson Reports Substantial Earnings Growth in Q1 2025** In a remarkable financial performance, Johnson & Johnson announced a substantial increase in net earnings for the first quarter of 2025, reaching $10.999 billion. This marks a significant rise from the $3.255 billion reported in the same quarter of 2024, and the company's diluted earnings per share (EPS) escalated to $4.54. This impressive year-over-year growth of 238.8% underscores the firm's improved profitability, facilitated by effective cost management and well-executed strategic initiatives. A key development contributing to this financial upturn has been Johnson & Johnson's strategic acquisition of Intra-Cellular Therapies. This acquisition not only broadens the company's product portfolio but also consolidates its position in the mental health sector, a market poised for rapid expansion. This strategic maneuver is set to pave the way for the company's sustained growth by capturing emerging opportunities in this burgeoning market. Moreover, Johnson & Johnson's liquidity position has significantly strengthened, reflected by the notable increase in cash and cash equivalents, which surged from $24.105 billion at the close of 2024 to $38.474 billion as of March 30, 2025. This was largely supported by robust cash flows from financing activities, providing the company with enhanced financial flexibility. The increased liquidity arms Johnson & Johnson with the capacity for strategic investments and efficient operational management, positioning it well to navigate future growth trajectories. As Johnson & Johnson continues to execute its growth strategies effectively, both its financial health and market positioning appear robust and promising, underscoring its commitment to delivering value to shareholders and contributing positively to the healthcare sector.

Chinese News:
强生埃万妥单抗注射液联合化疗方案在华获批用于EGFR TKI经治后局部晚期或转移性非小细胞肺癌患者治疗 4月25日，强生宣布，旗下创新治疗药物埃万妥单抗注射液正式获得国家药品监督管理局批准，与卡铂和培美曲塞联合给药，适用于治疗携带表皮生长因子受体（EGFR）19号外显子缺失或21号外显子L858R置换突变且在EGFR酪氨酸激酶抑制剂治疗期间或之后疾病进展的局部晚期或转移性非鳞状非小细胞肺癌（NSCLC）成人患者。 此次获批标志着埃万妥单抗在中国迎来了今年第二个肺癌适应症。此前，该药于今年2月获批用于治疗携带EGFR 20号外显子插入突变的局部晚期或转移性非小细胞肺癌成人患者的一线治疗。

Japanese News:
Johnson & Johnson（ティッカーシンボル：JNJ）は、2025年第1四半期（Q1）の決算を発表しました。実績は予想を上回る結果となり、EPSは2.77ドルで、予想の2.58ドルを上回りました。売上高は21.89Bドルで、予想の21.57Bドルを上回り、前年同期比で2.9%の増加を記録しました。 2025年通年ガイダンスの上方修正 Johnson & Johnsonは、2025年通年のガイダンスを上方修正しました。EPSの予想は10.49ドルから10.50～10.70ドルに引き上げられ、売上高の予想も90.33Bドルから91.0Bドル～91.8Bドルに改訂されました。これにより、同社は今後の成長に対する楽観的な見通しを示しています。

Spanish News:
El 15 de abril de 2025, antes de la apertura del mercado, todas las miradas estarán puestas en las acciones de Johnson & Johnson. La compañía estadounidense presentará sus resultados del primer trimestre del año en un contexto marcado por incertidumbres económicas, litigios pendientes y desafíos en sus principales divisiones de negocio. ¿Qué esperar de los resultados de Johnson & Johnson? Se espera que Johnson & Johnson registre un beneficio por acción (BPA) ajustado de 2,64 dólares, con ingresos cercanos a los 21.640 millones de dólares. Este dato refleja una estabilidad respecto al mismo periodo del año anterior, lo que, en tiempos de volatilidad, podría interpretarse como una señal de solidez. Esta previsión se apoya en el buen desempeño de dos de sus áreas clave: el negocio farmacéutico y la división de tecnología médica (MedTech). Ambos segmentos han sido fundamentales en el desempeño positivo reciente de las acciones de Johnson & Johnson. Aspectos clave que influirán en las acciones de Johnson & Johnson En el área farmacéutica, las ventas de medicamentos como Darzalex, Erleada y Spravato siguen siendo un motor clave. Sin embargo, algunos analistas están observando de cerca el impacto potencial de los competidores biosimilares sobre productos populares como Stelara. En cuanto a la tecnología médica, la adquisición de Shockwave Medical, especializada en tratamientos cardiovasculares, está comenzando a tener un impacto positivo en los ingresos de esta división. Esta operación, cerrada en 2024, refuerza el posicionamiento de J&J en el sector de dispositivos médicos. El gran reto: los litigios por el talco Un aspecto que sigue generando incertidumbre en torno a las acciones de Johnson & Johnson es el litigio relacionado con el uso de talco en productos para bebés, que ha resultado en numerosas demandas. La compañía ha intentado reducir el impacto económico de estos litigios mediante maniobras legales, pero los tribunales han rechazado sus intentos de trasladar la responsabilidad a filiales en bancarrota. Este asunto sigue generando incertidumbre a medio plazo. Evolución de las acciones de Johnson & Johnson En 2025, las acciones de Johnson & Johnson han acumulado un aumento cercano al 7%, superando el rendimiento medio del mercado. En la sesión previa a la presentación de resultados, las acciones cotizaban alrededor de los 154,36 dólares, mostrando una notable fortaleza a pesar de los desafíos legales y económicos. La publicación de los resultados será un punto clave. Una sorpresa positiva en ingresos, beneficios o perspectivas futuras podría dar un nuevo impulso a las acciones de J&J, mientras que señales de debilidad o noticias negativas sobre los litigios podrían frenar esta recuperación. Análisis técnico de Johnson & Johnson El gráfico diario de las acciones de Johnson & Johnson muestra una estructura bajista a corto plazo, especialmente tras la fuerte caída desde la zona de los 170 dólares. El precio ha perdido la media móvil de 200 sesiones (línea azul, ahora amarilla), lo que ha incrementado la presión vendedora. En el rebote más reciente, las acciones han logrado recuperar niveles clave como los 151,05 dólares, pero siguen cotizando por debajo de resistencias importantes como la zona de los 155 dólares (media móvil descendente a largo plazo). Por otro lado, el MACD refleja un intento de giro al alza tras un largo período de caídas. No obstante, el histograma sigue en terreno negativo, lo que sugiere que el movimiento actual podría ser simplemente un rebote dentro de la tendencia bajista dominante. Si el precio no supera de manera consistente los 155 dólares, el riesgo de nuevas caídas hacia los 143 o incluso los 139 dólares sigue siendo relevante.

Greek News:
Θετικά αποτελέσματα ανακοίνωσε η Johnson & Johnson για το πρώτο τρίμηνο του 2025, υπερβαίνοντας τις εκτιμήσεις των αναλυτών τόσο σε επίπεδο κερδών όσο και εσόδων. Τα προσαρμοσμένα κέρδη ανά μετοχή διαμορφώθηκαν στα 2,77 δολάρια, υψηλότερα από την πρόβλεψη των 2,58 δολαρίων. Τα έσοδα ανήλθαν στα 21,9 δισ. δολάρια, επίσης πάνω από την πρόβλεψη των 21,57 δισ. Σε ετήσια βάση, τα συνολικά έσοδα αυξήθηκαν κατά 4,2%, με τις πωλήσεις στις Ηνωμένες Πολιτείες να ενισχύονται κατά 5,9% και τις διεθνείς πωλήσεις να καταγράφουν άνοδο 2,1%. Κομβική παραμένει η συμβολή των σκευασμάτων DARZALEX και TREMFYA, τα οποία συνέχισαν να παρουσιάζουν ισχυρούς ρυθμούς ανάπτυξης. Η διοίκηση της εταιρείας διατηρεί εκτιμήσεις για οργανική αύξηση των πωλήσεων μεταξύ 3,3% και 4,3% για το σύνολο του έτους, ενώ μεγαλύτερη δυναμική αναμένεται κατά το δεύτερο εξάμηνο του 2025, λόγω προόδου στην έρευνα και νέων εγκρίσεων προϊόντων. Παρά την ισχυρή πορεία στα οικονομικά μεγέθη, η μετοχή της εταιρείας υποχωρεί οριακά κατά 0,39% στις προσυνεδριακές συναλλαγές, υποδηλώνοντας επιφυλακτικότητα των επενδυτών.

Question:
How is the company allocating capital (e.g., investments, share repurchases, dividends) based on its performance and market outlook from the news? Please quote all the relevant financial information from the financial statements supporting the finding(s), if any.

Answer:

Question: How is the company allocating capital (e.g., investments, share repurchases, dividends) based on its performance and market outlook from the news? Please quote all the relevant financial information from the financial statements supporting the finding(s), if any.